EirGenix’s Breast Cancer Biosimilar Receives Marketing Authorization by EC
(Adnkronos) – TAIPEI, Nov. 23, 2023 /PRNewswire/ — EirGenix Inc. (6589. TT) announced today that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to commercialise (150 mg, for intravenous
